A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Tirasemtiv (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms VITALITY-ALS
- Sponsors Cytokinetics
- 04 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.
- 04 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2017.
- 27 Apr 2017 According to a Cytokinetics media release, Data Monitoring Committee recommended the continuation of this study without modification.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History